Loading clinical trials...
Loading clinical trials...
A Safety Follow-up Study of a Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Cellgram-ED (Autologous Bone Marrow-Derived Mesenchymal Stem Cells) in Patients With Post-Radical Prostatectomy Erectile Dysfunction
This phase II clinical trial with safety follow-up is designed to evaluate the efficacy and safety of Cellgram-ED (autologous bone marrow-derived mesenchymal stem cells) administered via intracavernous injection in patients with erectile dysfunction after radical prostatectomy.
Safety evaluations will be conducted over a period of 4 years (±30 days) from the completion date of the parent clinical trial. During the safety follow-up period, participants will be monitored for adverse events, serious adverse events, and other clinically relevant safety parameters to assess the long-term safety profile of Cellgram-ED.
Age
19 - 80 years
Sex
MALE
Healthy Volunteers
No
Asan medical center
Seoul, South Korea
Ewha womans university medical center
Seoul, South Korea
Samsung medical center
Seoul, South Korea
Seoul ST. Mary's hospital
Seoul, South Korea
Start Date
December 26, 2024
Primary Completion Date
January 10, 2030
Completion Date
January 10, 2030
Last Updated
February 24, 2026
32
ESTIMATED participants
Lead Sponsor
Pharmicell Co., Ltd.
NCT07480161
NCT07460960
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06167733